CO2025000062A2 - Dominios variables únicos de inmunoglobulina que se dirigen al receptor de linfocitos t - Google Patents
Dominios variables únicos de inmunoglobulina que se dirigen al receptor de linfocitos tInfo
- Publication number
- CO2025000062A2 CO2025000062A2 CONC2025/0000062A CO2025000062A CO2025000062A2 CO 2025000062 A2 CO2025000062 A2 CO 2025000062A2 CO 2025000062 A CO2025000062 A CO 2025000062A CO 2025000062 A2 CO2025000062 A2 CO 2025000062A2
- Authority
- CO
- Colombia
- Prior art keywords
- present technology
- isvds
- polypeptides
- variable domains
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305869 | 2022-06-14 | ||
| PCT/EP2023/065925 WO2023242247A1 (en) | 2022-06-14 | 2023-06-14 | Immunoglobulin single variable domains targeting t cell receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2025000062A2 true CO2025000062A2 (es) | 2025-01-23 |
Family
ID=82404277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2025/0000062A CO2025000062A2 (es) | 2022-06-14 | 2025-01-07 | Dominios variables únicos de inmunoglobulina que se dirigen al receptor de linfocitos t |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109965A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4540286A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025530888A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250023503A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119630705A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129614A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023290487A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3259417A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2025000062A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL317588A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024015501A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202415678A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023242247A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260068087A (ko) * | 2023-09-04 | 2026-05-13 | 사노피 | 글리피칸-3-발현 종양의 치료에 사용하기 위한 폴리펩티드 |
| WO2026052756A1 (en) | 2024-09-05 | 2026-03-12 | Ablynx Nv | Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof |
| WO2026078159A1 (en) | 2024-10-10 | 2026-04-16 | Ablynx Nv | Immune cell engagers and methods comprising the same |
| WO2026132542A2 (en) * | 2024-12-20 | 2026-06-25 | Ablynx Nv | Immunoglobulin single variable domains targeting pd-1 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| AU2002362197A1 (en) * | 2001-12-28 | 2003-07-24 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| LT3466972T (lt) | 2011-06-23 | 2026-06-25 | Ablynx Nv | Serumo albuminą surišantys baltymai |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| IL254039B2 (en) * | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| HRP20191800T1 (hr) | 2015-05-13 | 2019-12-27 | Ablynx N.V. | Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti |
| HUE057241T2 (hu) | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| US11840569B2 (en) | 2016-11-16 | 2023-12-12 | Ablynx N.V. | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| WO2018104444A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP4442709A3 (en) | 2017-01-17 | 2024-12-25 | Ablynx NV | Improved serum albumin binders |
| EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
| PH12023500013A1 (en) * | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| CA3205422A1 (en) * | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| WO2022129637A1 (en) * | 2020-12-18 | 2022-06-23 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
-
2023
- 2023-06-14 CN CN202380057045.XA patent/CN119630705A/zh active Pending
- 2023-06-14 JP JP2024573474A patent/JP2025530888A/ja active Pending
- 2023-06-14 AU AU2023290487A patent/AU2023290487A1/en active Pending
- 2023-06-14 TW TW112122236A patent/TW202415678A/zh unknown
- 2023-06-14 CA CA3259417A patent/CA3259417A1/en active Pending
- 2023-06-14 WO PCT/EP2023/065925 patent/WO2023242247A1/en not_active Ceased
- 2023-06-14 KR KR1020257000924A patent/KR20250023503A/ko active Pending
- 2023-06-14 AR ARP230101523A patent/AR129614A1/es unknown
- 2023-06-14 IL IL317588A patent/IL317588A/en unknown
- 2023-06-14 EP EP23732562.6A patent/EP4540286A1/en active Pending
- 2023-06-14 US US18/334,642 patent/US20240109965A1/en active Pending
-
2024
- 2024-12-13 MX MX2024015501A patent/MX2024015501A/es unknown
-
2025
- 2025-01-07 CO CONC2025/0000062A patent/CO2025000062A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR129614A1 (es) | 2024-09-11 |
| AU2023290487A1 (en) | 2025-01-30 |
| EP4540286A1 (en) | 2025-04-23 |
| IL317588A (en) | 2025-02-01 |
| KR20250023503A (ko) | 2025-02-18 |
| CA3259417A1 (en) | 2023-12-21 |
| TW202415678A (zh) | 2024-04-16 |
| MX2024015501A (es) | 2025-02-10 |
| US20240109965A1 (en) | 2024-04-04 |
| WO2023242247A1 (en) | 2023-12-21 |
| WO2023242247A8 (en) | 2024-12-19 |
| JP2025530888A (ja) | 2025-09-18 |
| CN119630705A (zh) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022013525A2 (es) | Anticuerpos contra sars-cov-2 y métodos para usarlos | |
| MX2020012587A (es) | Anticuerpos anti-cd3 y usos de estos. | |
| BR112021026376A2 (pt) | Proteínas de fusão flt3l-fc e métodos de uso | |
| ECSP20082991A (es) | Agentes aglutinantes del psma y usos de estos | |
| CR20220594A (es) | Proteins comprising cd3 antigen binding domains and uses thereof | |
| EA202190435A1 (ru) | Конструкции на основе антител для связывания cldn18.2 и cd3 | |
| CO2024012032A2 (es) | Anticuerpos multiespecíficos que se unen a il-4, il-3 y/o tslp y usos de los mismos | |
| EA201990243A1 (ru) | Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения | |
| MX2022007035A (es) | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. | |
| BR112022004995A2 (pt) | Anticorpos biespecíficos contra ceacam5 e cd3 | |
| MX2024015501A (es) | Dominios variables unicos de inmunoglobulina que se dirigen al receptor de linfocitos t | |
| MX2021003608A (es) | Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente. | |
| EA201890390A1 (ru) | БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3 | |
| WO2019165122A8 (en) | Neutralizing antibodies to hiv-1 env and their use | |
| BR112012016135A2 (pt) | proteínas de ligação de heterodímero e seus usos | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| WO2016179518A8 (en) | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof | |
| CR20220194A (es) | Moléculas de unión a pd-1 y métodos de uso de las mismas | |
| BR112016003369A2 (pt) | diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma | |
| BR112021019915A2 (pt) | Proteínas de ligação triespecíficas, métodos e usos dos mesmos | |
| MX2024007314A (es) | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden. | |
| CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
| CO2024000024A2 (es) | Moléculas de unión a gpc3 | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t |